AZD 8871

Drug Profile

AZD 8871

Alternative Names: AZD8871

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Class Antiasthmatics; Antibronchitics
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease
  • Phase I Asthma

Most Recent Events

  • 05 Jul 2018 Safety and efficacy data from a phase IIa trial in Chronic obstructive pulmonary disease presented at 114th International Conference of the American Thoracic Society (ATS-2018)
  • 03 Nov 2017 AstraZeneca completes a phase I trial in Healthy Japanese volunteers in United Kingdom (NCT03159442)
  • 09 Sep 2017 Efficacy, safety and pharmacokinetcs data from a phase I trial in Asthma and Chronic obstructive pulmonary diseases presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top